| Amarin

Amarin Provides Preliminary 2020 Results and 2021 Outlook

Submitted by amarin on Thu, 01/07/2021 - 11:05

Read more about Amarin Provides Preliminary 2020 Results and 2021 Outlook

Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA ® (icosapent ethyl) Expected in Late January or February 2021 DUBLIN,

Statement of changes in beneficial ownership of securities

Submitted by amarin on Wed, 01/06/2021 - 01:08

Home

Read more about Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Submitted by amarin on Wed, 01/06/2021 - 01:06

Home

Read more about Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Submitted by amarin on Wed, 01/06/2021 - 01:06

Home

Read more about Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Submitted by amarin on Wed, 01/06/2021 - 01:05

Home

Read more about Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Submitted by amarin on Wed, 01/06/2021 - 01:05

Home

Read more about Statement of changes in beneficial ownership of securities

39th Annual J.P. Morgan Healthcare Conference

Submitted by amarin on Mon, 01/04/2021 - 12:32

Home

Read more about 39th Annual J.P. Morgan Healthcare Conference

Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference

Submitted by amarin on Mon, 01/04/2021 - 11:06

Home

Read more about Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

NLA Scientific Sessions 2020 Late-Breakers Discussion

Submitted by amarin on Thu, 12/17/2020 - 15:45

Home

Read more about NLA Scientific Sessions 2020 Late-Breakers Discussion

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results

Submitted by amarin on Mon, 12/14/2020 - 10:00

Home

Read more about Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results

REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms

Subscribe to